Evaluating Machine Learning in Health Economics

By Sumona Bose

January 22, 2024

Introduction

Advances in Machine Learning and Artificial Intelligence (AI) have the potential to transfigure the healthcare industry, offering tremendous benefits to patients. While predictive analytics using ML are already widely used in healthcare operations and care delivery, there is growing interest in exploring how ML can be applied to Health Economics and Outcomes Research (HEOR). The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) established an emerging good practices task force specifically focused on the application of ML in HEOR. The task force identified five key areas where ML could enhance HEOR methodologies.

Machine Learning Functions

The first area is cohort selection, where ML can help identify samples with greater specificity in terms of inclusion criteria. This can lead to more accurate and targeted research, ultimately improving patient outcomes. The second area is the identification of independent predictors and covariates of health outcomes. ML algorithms can analyze large datasets to identify factors that contribute to specific health outcomes, providing valuable insights for researchers and policymakers.

Predictive analytics of health outcomes is another area where ML can make a significant impact. ML algorithms can analyze high-cost or life-threatening health outcomes, helping healthcare providers and policymakers make informed decisions and allocate resources effectively. The fourth area is causal inference, where ML methods such as targeted maximum likelihood estimation or double-debiased estimation can help produce reliable evidence more quickly. This can accelerate the research process and enable faster decision-making.

HEOR and Machine Learning: PALISADE Checklist

ML can be applied to the development of economic models, reducing structural, parameter, and sampling uncertainty in cost-effectiveness analysis. By leveraging ML algorithms, researchers can improve the accuracy and reliability of economic models, leading to more robust and informed decision-making. Overall, ML facilitates HEOR through the meaningful and efficient analysis of big data. However, there is a need for transparency in how ML methods deliver solutions, particularly in unsupervised circumstances. The lack of transparency increases the risk to providers and decision-makers when using ML results.

To address this issue, the task force developed the PALISADE Checklist. This checklist serves as a guide for balancing the potential applications of ML with the need for transparency in methods development and findings. By following this checklist, researchers and decision-makers can ensure that ML solutions are both useful and transparent in healthcare analytics.

Conclusion

As AI continues to advance, it is crucial for the healthcare industry to embrace these technologies and leverage their potential to improve patient outcomes and drive value-based healthcare. By incorporating ML into HEOR methodologies, researchers can gain valuable insights, enhance decision-making, and strengthen healthcare systems.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.